DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA561229
Title:
Acute Lung Injury: Making the Injured Lung Perform Better and Rebuilding Healthy Lungs
Descriptive Note:
Annual rept. 1 Jul 2010-30 Jun 2011
Corporate Author:
BOSTON MEDICAL CENTER CORP MA
Report Date:
2011-07-01
Pagination or Media Count:
12.0
Abstract:
Acute lung injury ALI is a complex syndrome characterized by diffuse injury to the alveolar epithelial surface resulting in a marked impairment in the ability to oxygenate blood. The goals of our application are to facilitate the rational development of ventilatory and cell based strategies to treat the ALI. As we have previously noted, ALI is associated with severe infections, exposure to toxins, trauma, and multiple blood transfusions all of these conditions afflict patients with cancer. This is compounded by the fact that cancer patients are vulnerable to development of ALI as a result of the immunosuppressive effects of chemotherapy and the debilitating effects of cancer. It is also important to note that active military personnel are also at risk for ALI because of battle induced trauma and the consequent need for blood transfusions. In Project 1, we proposed to develop a new mode of ventilation variable ventilation that will minimize the toxic effects of conventional mechanical ventilation in patients with ALI. In the past year, we resolved all technical and engineering barriers, and have developed a fully functional variable ventilator running on a Covidien Puritan- Bennet 840 ventilator platform. We completed in-laboratory testing to confirm the correct function and alarm functionalities of the system. We are in the final phases of now completing a FDA Investigational Device Exemption IDE submission, which we plan to submit to FDA this month. Once received, we will submit the final protocol to the Department of Defense Human Research Protection Office HRPO for approval. In support of this goal, we monitored the clinical characteristics of the patients with respiratory failure in our intensive care units so that we can develop the optimal recruitment strategy for an informative and effective clinical trial once final FDA IDE and DoD HRPO approvals are in hand. In the preclinical Project 2 study in mice, we have continued to be focused on optimizing
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
